Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
Open Access
- 17 May 2023
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 21 (6) , e438-e448
Abstract
No abstract availableKeywords
Funding Information
- Stiftelsen Konung Gustaf V:s Jubileumsfond
- Cancerfonden (CAN 2016/393)
- Cancerfonden (221996)
- Cancerfonden (221995)
- Cancerfonden (190171)
- Cancerfonden (190288)
- Cancerfonden (CAN 2016/391)
- Stockholms Läns Landsting (20180022)
- Stockholms Läns Landsting (20160051)
- Stockholms Läns Landsting (20200068)
This publication has 31 references indexed in Scilit:
- Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit NovumEuropean Urology, 2018
- Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial CancerEuropean Urology, 2018
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib StudyJournal of Clinical Oncology, 2017
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaNew England Journal of Medicine, 2017
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2017
- Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death ( PD )‐1 or PD ligand 1 inhibitor therapyBJU International, 2016
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial TractJournal of Clinical Oncology, 2009
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924Journal of Clinical Oncology, 2001